Communiqués MetaVia Inc.

Actions

MTVA

US64132R5037

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
1,660 ^USD	-0,60%		-1,19%	-80,29%

09/09	MetaVia annonce des résultats précliniques confirmant le rationnel biologique de la réduction du tour de taille par le DA-1726	CI
06/08	MetaVia Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

09/09	MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction	PR
06/08	MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update	PR
09/07	MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity	PR
17/06	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum	PR
08/06	MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential	PR
04/06	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference	PR
27/05	MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH	PR
20/05	MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH	PR
18/05	MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions	PR
14/05	MetaVia : Summary Presentation May 2026	PU
14/05	MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update	PR
11/05	MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026	PR
10/04	MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity	PR
26/03	MetaVia : Summary Investor Presentation March 2026	PU
26/03	MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update	PR
18/03	MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control	PR
12/03	MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035	PR
04/03	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum	PR
24/02	MetaVia : Summary Presentation February 2026	PU
17/02	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference	PR
13/02	MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041	PR
04/02	MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel	PR
19/01	MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option	AQ
16/01	MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option	PR
15/01	MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering	PR